Overview

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants

Status:
NOT_YET_RECRUITING

Trial end date:
2028-04-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) vaccine in infants with the first dose administered at 6 months of age (MOA) or 6 weeks of age (WOA).

Phase:

PHASE2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

13-valent pneumococcal vaccine
Sodium Chloride